High-affinity CRF1 receptor antagonist NBI-34041: Preclinical and clinical data 
suggest safety and efficacy in attenuating elevated stress response

Ising, M.; Zimmermann, U. S.; Kuenzel, H. E.; Uhr, M.; Foster, A. C.; Learned-Coughlin, S. M.; Holsboer, F.; Grigoriadis, D. E.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

High-affinity CRF1 receptor antagonist NBI-34041: Preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response

MPS-Authors

/persons/resource/persons80379

Ising, M.
AG Ising, Marcus, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

Zimmermann, U. S.
Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80415

Kuenzel, H. E.
AG Steiger, Axel, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80563

Uhr, M.
AG Uhr, Manfred, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80372

Holsboer, F.
Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Ising, M., Zimmermann, U. S., Kuenzel, H. E., Uhr, M., Foster, A. C., Learned-Coughlin, S. M., et al. (2007). High-affinity CRF1 receptor antagonist NBI-34041: Preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology, 32(9), 1941-1949.

Cite as: https://hdl.handle.net/11858/00-001M-0000-000E-9676-D

Abstract

There is no abstract available